Breaking News

Error rendering macro 'rss' : java.io.IOException: Failed to recover from an exception: http://environmentalhealthnews.org/archives_rss.jsp?sm=&tn=1title%2Clede%2Cdescription%2Ctext%2Csubject%2Cpublishername%2Ccoverage%2Creporter&tv=toxicology&ss=1

Sick Building Syndrome

Authors

Overview


Sick building syndrome (SBS) is a combination of ailments (a syndrome) associated with an individual's place of work (office building), school, or residence. The term "sick building syndrome" (SBS) is used to describe situations in which building occupants experience acute health effects that appear to be linked to time spent in a building, but no specific illness or cause can be identified. The complaints may be localized in a particular room or zone, or may be widespread throughout the building. In contrast, the term "building related illness" (BRI) is used when symptoms of diagnosable illness are identified and can be attributed directly to airborne building contaminants (US EPA). An example of BRI is Legionnaire's Disease, attributed to specific bacteria.

A 1984 World Health Organization report on sick building syndrome suggested that up to 30% of new and remodeled buildings worldwide may be linked to symptoms of SBS. Most sick building syndrome complaints are related to poor indoor air quality.

The health complaints often include: (SBS) "... symptoms associated with acute discomfort, e.g., headache; eye, nose, or throat irritation; dry cough; dry or itchy skin; dizziness and nausea; difficulty in concentrating; fatigue; and sensitivity to odors. The cause of the symptoms is not known. (BRI) include: ...symptoms such as cough; chest tightness; fever, chills; and muscle aches. The symptoms can be clinically defined and have clearly identifiable causes" (US EPA).

"Damp building / mold-related complaints may include allergic, hypersensitivity, toxicity - including immunotoxicity and neurotoxicity, mucous membrane or trigeminal nerve irritation, or infectious reactions" (Vojdani).  

"Damp buildings produce an environment where molds and bacteria grow: One consequence of indoor dampness is new or enhanced growth of fungi and other microbial agents, mold growth is usually accompanied by bacterial growth, mold and bacterial growth produce health effects, some research on fungi and bacteria focuses on specific components that may be  responsible for particular health effects: spores and hyphal fragments of fungi, spores and cells of bacteria, allergens of microbial origin, structural components of fungal and bacterial cells, and such products as microbial volatile organic compounds (MVOC's) and mycotoxins, release of these components varies..., bacteria and fungi can cause allergic responses, non-allergic, toxic and inflammatory effects, excessive indoor dampness is a public health problem, inhalation fevers are associated with occupational exposure to high concentrations of organic materials, including bacteria, fungi, and their associated constituents and emissions" (IOM, 2004).

This is an emerging illness, with complaints stemming from construction practices that began in the 1970s. Health complaints may be transient or become chronic, in some cases.

Sick building research shows that building-related symptoms are associated with building characteristics including dampness, cleanliness, and ventilation (NIOSH). Causes are frequently pinned down to flaws in the heating, ventilation, and air conditioning (HVAC) systems. Other causes have been attributed to contaminants produced by outgassing of some types of building materials, volatile organic compounds, molds (see mold health issues), improper exhaust ventilation of light industrial chemicals used within, location of fresh-air intake, or lack of adequate air filtration (see Minimum Efficiency Reporting Value).

Symptoms are often dealt with after-the-fact by boosting the overall turnover rate of fresh air exchange with outside air, but the new green building design goal should be to avoid most of the SBS problem sources in the first place, minimize the ongoing use of VOC cleaning compounds, and eliminate conditions that encourage mold growth.

References


  1. Sick Building Syndrome Solutions in Australia, ecolibria - Building Biology http://www.ecolibria.au.com/
  2. IAQ Publications - Sick Building Syndrome Fact Sheet http://www.epa.gov/iaq/pubs/sbs.html
  3. Boston Phoenix article on SBS complaints at Boston City Hall http://www.bostonphoenix.com/boston/news_features/top/features/documents/02229143.htm
  4. Telegraph article about a study linking SBS to job stress http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2006/03/23/nsick23.xml&sSheet=/news/2006/03/23/ixhome.html
  5. Inquiry into Sick Building Syndrome by NSW Parliament, Australia http://143.119.255.90/isysquery/8b805f4d-3a9a-471c-8938-9962145ed2fd/1/doc.
  6. Chemical Injury Information Network http://ciin.org/
  7. US EPA Indoor Air Facts No. 4 (revised) Sick Building Syndrome http://www.epa.gov/iaq/pubs/sbs.html
  8. Rutgers University Radon and Indoor Air Quality Tools for Schools Program and IAQ Video http://www.rutgers.edu/iaq
  9. IEQ Overview (CDC, NIOSH) http://www.cdc.gov/niosh/topics/indoorenv/
  10. Mold and Mildew Awareness, Indoor Air Quality (National Institute of Health) http://www.niehs.nih.gov/health/topics/agents/mold/docs/mold.pdf
  11. Health Effects of Mold (Vojdani) http://www.schoolmoldhelp.org/content/view/596/66/
  12. Sick Building Symptoms (The Center for School Mold Help) http://www.schoolmoldhelp.org/content/category/4/53/66/
  13. IOM: Damp Indoor Spaces and Health (2004) http://www.nap.edu/books/0309091934/html; SMH summary: https://www.schoolmoldhelp.org/content/view/191/65/
  14. E. C. Anyanwu : The validity of the environmental neurotoxic effects of toxigenic molds and mycotoxins. The Internet Journal of Toxicology. 2008 Volume 5 Number 2
  15. Vojdani A, Campbell AW, Kashanian A, Vojdani E. Antibodies against molds and mycotoxins following exposure to toxigenic fungi in a water-damaged building. Arch Environ Health. 2003 Jun;58(6):324-36. (s)
  16. Kilburn KH. Indoor mold exposure associated with neurobehavioral and pulmonary impairment: a preliminary report. Arch Environ Health. 2003 Jul;58(7):390-8. (s)
  17. Anyanwu E, Campbell AW, Jones J, Ehiri JE, Akpan AI. The neurological significance of abnormal natural killer cell activity in chronic toxigenic mold exposures. ScientificWorldJournal. 2003 Nov 13;3:1128-37. (s)
  18. Gray MR, Thrasher JD, Crago R, Madison RA, Arnold L, Campbell AW, Vojdani A. Mixed mold mycotoxicosis: immunological changes in humans following exposure in water-damaged buildings. Arch Environ Health. 2003 Jul;58(7):410-20. (s)
  19. Campbell AW, Anyanwu EC, Vojdani A. Combination of high-dose intravenous immunoglobulins and itraconozole in treating chronic mycotic demyelinating optic neuritis. ScientificWorldJournal. 2003 Aug 2;3:640-6. (s)
  20. Crago BR, Gray MR, Nelson LA, Davis M, Arnold L, Thrasher JD. Psychological, neuropsychological, and electrocortical effects of mixed mold exposure. Arch Environ Health. 2003 Aug;58(8):452-63. (s)
  21. Vojdani A, Thrasher JD, Madison RA, Gray MR, Heuser G, Campbell AW. Antibodies to molds and satratoxin in individuals exposed in water-damaged buildings. Arch Environ Health. 2003 Jul;58(7):421-32. (s)
  22. Campbell AW, Thrasher JD, Madison RA, Vojdani A, Gray MR, Johnson A. Neural autoantibodies and neurophysiologic abnormalities in patients exposed to molds in water-damaged buildings. Arch Environ Health. 2003 Aug; 58(8): 464-74. (s)
  23. Gordon WA, Cantor JB, Johanning E, Charatz HJ, Ashman TA, Breeze JL, Haddad L, Abramowitz S. Cognitive impairment associated with toxigenic fungal exposure: a replication and extension of previous findings. Appl Neuropsychol. 2004;11(2):65-74. (s)
  24. Anyanwu EC, Morad M, Campbell AW. Metabolism of mycotoxins, intracellular functions of vitamin B12, and neurological manifestations in patients with chronic toxigenic mold exposures. A review. ScientificWorldJournal. 2004 Aug 26;4:736-45. (s)
  25. Vojdani A, Kashanian A, Vojdani E, Campbell AW. Saliva secretory IgA antibodies against molds and mycotoxins in patients exposed to toxigenic fungi. : Immunopharmacol Immunotoxicol. 2003 Nov;25(4):595-614. (s)
  26. Anyanwu E, Campbell AW, Vojdani A, Ehiri JE, Akpan AI. Biochemical changes in the serum of patients with chronic toxigenic mold exposures: a risk factor for multiple renal dysfunctions. ScientificWorldJournal. 2003 Nov 3;3:1058-64. (s)
  27. Anyanwu E, Ehiri J, Akpan AI. Application, effectiveness, and limitations of the electrophysiological diagnosis of neurotoxic effects of chronic environmental mycotoxins in humans. Int J Adolesc Med Health. 2004 Apr-Jun;16(2):107-18. (s)
  28. Reijula K, Tuomi T. Mycotoxins of aspergilli: exposure and health effects. Front Biosci. 2003 May 1;8:s232-5. (s)
  29. Bunger J, Westphal G, Monnich A, Hinnendahl B, Hallier E, Muller M. Cytotoxicity of occupationally and environmentally relevant mycotoxins. Toxicology. 2004 Oct 1;202(3):199-211. (s)
  30. Rylander R, Etzel R. Introduction and summary: workshop on children's health and indoor mold exposure. Environ Health Perspect. 1999 Jun;107 Suppl 3:465-8. (s)
  31. Portnoy JM, Kwak K, Dowling P, VanOsdol T, Barnes C. Health effects of indoor fungi. Ann Allergy Asthma Immunol. 2005 Mar;94(3):313-9; quiz 319-22, 390. (s)
  32. Edmondson DA, Nordness ME, Zacharisen MC, Kurup VP, Fink JN. Allergy and "toxic mold syndrome". Ann Allergy Asthma Immunol. 2005 Feb;94(2):234-9. (s)
  33. Anyanwu EC, Mycotoxins and antifungal drug interactions: implications in the treatment of illnesses due to indoor chronic toxigenic mold exposures. ScientificWorldJournal. 2004a Mar 12;4:167-77. (s)
  34. Jarvis BB, Miller JD. Mycotoxins as harmful indoor air contaminants. Appl Microbiol Biotechnol. 2005 Jan;66(4):367-72. Epub 2004 Nov 23. (s)
  35. Peraica M, Domijan AM. Contamination of food with mycotoxins and human health. Arh Hig Rada Toksikol. 2001 Mar;52(1):23-35 (s)
  36. Creppy EE. Update of survey, regulation and toxic effects of mycotoxins in Europe. Toxicol Lett. 2002 Feb 28;127(1-3):19-28 (s)
  37. Hussein HS, Brasel JM. Toxicity, metabolism, and impact of mycotoxins on humans and animals. Toxicology. 2001 Oct 15;167(2):101-34. (s)
  38. Rea WJ, Didriksen N, Simon TR, Pan Y, Fenyves EJ, Griffiths B. (s)
  39. Effects of toxic exposure to molds and mycotoxins in building-related illnesses. Arch Environ Health. 2003 Jul;58(7):399-405. (s)
  40. Anyanwu, E C., Kanu, I, Nwachukwu, N C; Saleh, M A. Chronic Environmental exposure to Alternaria tenuis may manifest symptoms of neuropsychological illnesses: A study of 12 Cases. Journal of Applied Sciences & Environmental Management, Vol. 9, No. 3, 2005, pp. 45-51 (s)
  41. Jarvis BB. Chemistry and toxicology of molds isolated from water-damaged buildings. Adv Exp Med Biol. 2002;504:43-52. (s)
  42. Pitt JI. Toxigenic fungi and mycotoxins. Br Med Bull. 2000;56(1):184-92. (s)
  • No labels